Leen'T Hart

Leen'T Hart

Auto-generated profile, based on publicly available information

Leen'T Hart

Leiden University Medical Center

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Nature
Verified
Journal Article
Open access
PDF file
EMEirini Marouli
Eirini Marouli
MGMariaelisa Graff
Mariaelisa Graff
CGCarolina Medina Gomez
Carolina Medina Gomez
KLKen Sin Lo
Ken Sin Lo
AWAndrew R. Wood
Andrew R. Wood
GLGuillaume Lettre
Guillaume Lettre
Height is a highly heritable, classic polygenic trait with approximately 700 common associated variants identified through genome-wide association studies so far. Here, we report 83 height-associated coding variants with lower minor-allele frequencies (in the range of 0.1–4.8%) and effects of up to 2 centimetres per allele (such as those in IHH, STC2, AR and CRISPLD2), greater than ten times the average effect of common variants. In functional follow-up studies, rare height-increasing alleles of STC2 (giving an increase of 1–2 centimetres per allele) compromised proteolytic inhibition of PAPP-A and increased cleavage of IGFBP-4 in vitro, resulting in higher bioavailability of insulin-like growth factors. These 83 height-associated variants overlap genes that are mutated in monogenic growth disorders and highlight new biological candidates (such as ADAMTS3, IL11RA and NOX4) and pathways (such as proteoglycan and glycosaminoglycan synthesis) involved in growth. Our results demonstrate that sufficiently large sample sizes can uncover rare and low-frequency variants of moderate-to-large effect associated with polygenic human phenotypes, and that these variants implicate relevant genes and pathways.

1 February 2004 in Diabetes
Verified
Journal Article
Closed access
PDF file
JMJ. Antonie Maassen
J. Antonie Maassen
LHLeen. M. ‘t Hart
Leen. M. ‘t Hart
EEEinar van Essen
Einar van Essen
RHRob J. Heine
Rob J. Heine
GNGiel Nijpels
Giel Nijpels
HLHerman H.P.J. Lemkes
Herman H.P.J. Lemkes
Mutations in mitochondrial DNA (mtDNA) associate with various disease states. A few mtDNA mutations strongly associate with diabetes, with the most common mutation being the A3243G mutation in the mitochondrial DNA-encoded tRNA(Leu,UUR) gene. This article describes clinical characteristics of mitochondrial diabetes and its molecular diagnosis. Furthermore, it outlines recent developments in the pathophysiological and molecular mechanisms leading to a diabetic state. A gradual development of pancreatic β-cell dysfunction upon aging, rather than insulin resistance, is the main mechanism in developing glucose intolerance. Carriers of the A3243G mutation show during a hyperglycemic clamp at 10 mmol/l glucose a marked reduction in first- and second-phase insulin secretion compared with noncarriers. The molecular mechanism by which the A3243G mutation affects insulin secretion may involve an attenuation of cytosolic ADP/ATP levels leading to a resetting of the glucose sensor in the pancreatic β-cell, such as in maturity-onset diabetes of the young (MODY)-2 patients with mutations in glucokinase. Unlike in MODY2, which is a nonprogressive form of diabetes, mitochondrial diabetes does show a pronounced age-dependent deterioration of pancreatic function indicating involvement of additional processes. Furthermore, one would expect that all mtDNA mutations that affect ATP synthesis lead to diabetes. This is in contrast to clinical observations. The origin of the age-dependent deterioration of pancreatic function in carriers of the A3243G mutation and the contribution of ATP and other mitochondrion-derived factors such as reactive oxygen species to the development of diabetes is discussed.

8 August 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MIMetGen Investigators
MetGen Investigators
KZKaixin Zhou
Kaixin Zhou
DIDPP Investigators
DPP Investigators
AIACCORD Investigators
ACCORD Investigators
SYSook Wah Yee
Sook Wah Yee
EPEwan R Pearson
Ewan R Pearson
Ewan Pearson, Kathleen Giacomini and the Metformin Genetics Consortium perform a genome-wide association study for glycemic response to the antidiabetic drug metformin. They find an intronic allele of the GLUT2 glucose transporter gene that associates with greater metformin action, an effect that is more pronounced in obese individuals. Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear1. Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome-wide association study (GWAS), consisting of 13,123 participants of different ancestries. The C allele of rs8192675 in the intron of SLC2A2, which encodes the facilitated glucose transporter GLUT2, was associated with a 0.17% (P = 6.6 × 10−14) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry. rs8192675 was the top cis expression quantitative trait locus (cis-eQTL) for SLC2A2 in 1,226 human liver samples, suggesting a key role for hepatic GLUT2 in regulation of metformin action. Among obese individuals, C-allele homozygotes at rs8192675 had a 0.33% (3.6 mmol/mol) greater absolute HbA1c reduction than T-allele homozygotes. This was about half the effect seen with the addition of a DPP-4 inhibitor, and equated to a dose difference of 550 mg of metformin, suggesting rs8192675 as a potential biomarker for stratified medicine.

1 December 1998 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MKMatti K. Karvonen
Matti K. Karvonen
UPUllamari Pesonen
Ullamari Pesonen
MKMarkku Koulu
Markku Koulu
LNLeo Niskanen
Leo Niskanen
MLMarkku Laakso
Markku Laakso
MUMatti I.J. Uusitupa
Matti I.J. Uusitupa

15 October 2009 in Diabetes
Verified
Journal Article
Open access
ASAnnemarie M. Simonis-Bik
Annemarie M. Simonis-Bik
GNGiel Nijpels
Giel Nijpels
THTimon W. van Haeften
Timon W. van Haeften
JHJeanine J. Houwing-Duistermaat
Jeanine J. Houwing-Duistermaat
DBDorret I. Boomsma
Dorret I. Boomsma
LHLeen M. 'T Hart
Leen M. 'T Hart
OBJECTIVE: Recently, results from a meta-analysis of genome-wide association studies have yielded a number of novel type 2 diabetes loci. However, conflicting results have been published regarding their effects on insulin secretion and insulin sensitivity. In this study we used hyperglycemic clamps with three different stimuli to test associations between these novel loci and various measures of β-cell function. RESEARCH DESIGN AND METHODS: For this study, 336 participants, 180 normal glucose tolerant and 156 impaired glucose tolerant, underwent a 2-h hyperglycemic clamp. In a subset we also assessed the response to glucagon-like peptide (GLP)-1 and arginine during an extended clamp (n = 123). All subjects were genotyped for gene variants in JAZF1, CDC123/CAMK1D, TSPAN8/LGR5, THADA, ADAMTS9, NOTCH2/ADAMS30, DCD, VEGFA, BCL11A, HNF1B, WFS1, and MTNR1B. RESULTS: Gene variants in CDC123/CAMK1D, ADAMTS9, BCL11A, and MTNR1B affected various aspects of the insulin response to glucose (all P < 6.9 × 10−3). The THADA gene variant was associated with lower β-cell response to GLP-1 and arginine (both P < 1.6 × 10−3), suggesting lower β-cell mass as a possible pathogenic mechanism. Remarkably, we also noted a trend toward an increased insulin response to GLP-1 in carriers of MTNR1B (P = 0.03), which may offer new therapeutic possibilities. The other seven loci were not detectably associated with β-cell function. CONCLUSIONS: Diabetes risk alleles in CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B are associated with various specific aspects of β-cell function. These findings point to a clear diversity in the impact that these various gene variants may have on (dys)function of pancreatic β-cells.

11 July 2008 in Diabetologia
Verified
Journal Article
Closed access
PDF file
MGM. J. Groenewoud
M. J. Groenewoud
JDJ. M. Dekker
J. M. Dekker
AFA. Fritsche
A. Fritsche
ERE. Reiling
E. Reiling
GNG. Nijpels
G. Nijpels
THT. W. van Haeften
T. W. van Haeften